Non Small-Cell Lung Cancer Market Report, Size, Share & Outlook - 2024-2031 - Sanofi, Novartis AG & Pfizer Inc.

The global non-small cell lung cancer (NSCLC) market reached USD 25.4 billion in 2023 and is projected to grow to USD 47.4 billion by 2031, exhibiting a CAGR of 8.4% during the forecast period from 2024 to 2031.

The treatment strategy for non-small cell lung cancer (NSCLC) is primarily determined by the cancer's stage, which indicates its progression. Available treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The choice of treatment depends on various factors, such as the tumor's size and location, the extent of its spread to nearby lymph nodes or distant parts of the body, and the patient's overall health status. These factors collectively guide the personalized approach to managing NSCLC, aiming to maximize the effectiveness of the therapy while minimizing side effects.

Get a Free Sample Research PDF - https://www.datamintelligence.com/download-sample/non-small-cell-lung-cancer-market

Market Trends:

The Increasing FDA Approval for Non-Small-Cell Lung Cancer Treatment is Driving the Global Non-Small-Cell Lung Cancer Market Growth.

Recent FDA approvals have significantly expanded the treatment options for non-small cell lung cancer (NSCLC), especially for advanced and metastatic stages. In August 2022, the FDA granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic NSCLC whose tumors have a mesenchymal-epithelial transition (MET) exon 14 skipping mutation, identified through an FDA-approved test. This approval highlights the importance of targeted therapies in treating NSCLC, allowing for more personalized treatment approaches tailored to specific genetic mutations that drive cancer progression.

In addition, in November 2022, the FDA approved Regeneron Pharmaceuticals' Libtayo (cemiplimab-rwlc), a PD-1 inhibitor, in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC who do not have EGFR, ALK, or ROS1 aberrations. This combination therapy is approved for patients with locally advanced or metastatic tumors that are not suitable for definitive chemoradiation or surgical excision, and it can be used regardless of tumor histology or PD-L1 expression levels. These approvals underscore the ongoing advancements in NSCLC treatment, offering broader therapeutic options and emphasizing the growing role of immunotherapies and precision medicine in improving patient outcomes.

Market Segmentation:

By Drug Class: Epidermal Growth Factor Receptor (EGFR) Inhibitors, Anaplastic Lymphoma Kinase (ALK) Inhibitors, ROS1 Inhibitors, BRAF Inhibitors, Others.

By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Others.

By Treatment: Chemotherapy, Targeted Therapy, Immunotherapy.

By End-user: Hospitals, Homecare, Specialty Clinics, Others.

Get Customization Report: https://www.datamintelligence.com/customize/non-small-cell-lung-cancer-market

Major Players:

• Eli Lilly and Company
• Sanofi
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Pfizer Inc.
• AstraZeneca
• Boehringer Ingelheim
• Bristol-Myers Squibb Company
• Astellas

Regional Analysis:

The global Non Small-Cell Lung Cancer Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Non Small-Cell Lung Cancer Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Key Developments:

In December 2022, the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development under the Agency for Science, Technology and Research (A*STAR), partnered with XtalPi, a leading pharmaceutical technology company. This strategic collaboration aims to explore and develop new treatment options for non-small cell lung cancer (NSCLC). By leveraging EDDC's drug discovery expertise and XtalPi's advanced AI-driven drug design and predictive modeling capabilities, the partnership seeks to accelerate the identification and development of innovative therapies for NSCLC, addressing unmet medical needs in this challenging cancer type.

Related Reports:

Lung Cancer Therapeutics Market: https://datamintelligence.com/research-report/lung-cancer-therapeutics-market

Lung Cancer Surgery Market: https://datamintelligence.com/research-report/lung-cancer-surgery-market

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.